Skip to content
Oncology Research Hub

Ann Arbor, Michigan

Cancer clinical trials in Ann Arbor, MI

145 cancer studies are recruiting participants at sites in Ann Arbor as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Ann Arbor at a glance

  • 145 studies are recruiting at a site in Ann Arbor.
  • By phase: Phase 1 (16), Phase 1/2 (11), Phase 2 (43), Phase 2/3 (1), Phase 3 (45), Phase 4 (1), No phase (9), Observational (19). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (75), industry (46), government (24).
  • By research area: Lymphoma (35), Breast Cancer (34), Lung Cancer (31), Prostate Cancer (26), Pancreatic Cancer (11), Melanoma (8).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Ann Arbor

Basic details from each study's public record (the 30 most recently updated of 145). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Saint Joseph Mercy Hospital · University of Michigan Comprehensive Cancer Center
    Registry record
    NCT03418961 · updated
  2. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health Saint Joseph Mercy Hospital Ann Arbor · University of Michigan Rogel Cancer Center
    Registry record
    NCT05564377 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health Saint Joseph Mercy Hospital Ann Arbor · University of Michigan Rogel Cancer Center
    Registry record
    NCT06058377 · updated
  4. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Saint Joseph Mercy Hospital
    Registry record
    NCT03723928 · updated
  5. ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    ALX Oncology Inc.
    Study site
    University of Michigan Rogel Cancer Center
    Registry record
    NCT07007559 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Ann Arbor, MI on ClinicalTrials.gov.

Lung cancer studies recruiting in Ann Arbor

  1. A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Novelty Nobility, Inc.
    Study site
    University of Michigan Hospitals
    Registry record
    NCT06805825 · updated
  2. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Trinity Health Saint Joseph Mercy Hospital Ann Arbor
    Registry record
    NCT04267848 · updated
  3. Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

    • Observational
    • All ages
    • All sexes
    Sponsor
    Lung Cancer Mutation Consortium
    Study site
    University of Michigan
    Registry record
    NCT04712877 · updated
  4. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Michigan Rogel Cancer Center
    Registry record
    NCT06498635 · updated
  5. A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    VA Ann Arbor Healthcare System ( Site 0019)
    Registry record
    NCT07221474 · updated
  6. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    University of Michigan
    Registry record
    NCT07002034 · updated
  7. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    University of Michigan
    Registry record
    NCT07020221 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Ann Arbor, MI on ClinicalTrials.gov.

Prostate cancer studies recruiting in Ann Arbor

  1. Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    VA Office of Research and Development
    Study site
    VA Ann Arbor Healthcare System, Ann Arbor, MI
    Registry record
    NCT04038502 · updated
  2. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Trinity Health Saint Joseph Mercy Hospital Ann Arbor
    Registry record
    NCT03866382 · updated
  3. Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe

    • Observational
    • Ages 40 to 80
    • Male participants
    Sponsor
    University of Michigan Rogel Cancer Center
    Study site
    University of Michigan Rogel Cancer Center
    Registry record
    NCT05965180 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Ann Arbor, MI on ClinicalTrials.gov.

Melanoma studies recruiting in Ann Arbor

  1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health Saint Joseph Mercy Hospital Ann Arbor · University of Michigan Rogel Cancer Center
    Registry record
    NCT05136196 · updated
  2. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    University of Michigan
    Registry record
    NCT06246916 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Ann Arbor, MI on ClinicalTrials.gov.

Lymphoma studies recruiting in Ann Arbor

  1. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9545)
    Registry record
    NCT06717347 · updated
  2. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Trinity Health Saint Joseph Mercy Hospital Ann Arbor
    Registry record
    NCT03739814 · updated
  3. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Trinity Health Saint Joseph Mercy Hospital Ann Arbor
    Registry record
    NCT04269902 · updated
  4. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    C S Mott Children's Hospital
    Registry record
    NCT04546399 · updated
  5. Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Trinity Health Saint Joseph Mercy Hospital Ann Arbor
    Registry record
    NCT04840602 · updated
  6. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    C S Mott Children's Hospital · Trinity Health Saint Joseph Mercy Hospital Ann Arbor
    Registry record
    NCT05675410 · updated
  7. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Michigan Rogel Cancer Center
    Registry record
    NCT06337318 · updated
  8. Living Well With Lymphoma

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Michigan Rogel Cancer Center
    Study site
    University of Michigan
    Registry record
    NCT06047626 · updated
  9. A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    University of Michigan Health System
    Registry record
    NCT06084936 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Ann Arbor, MI on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Ann Arbor

  1. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

    • Phase 2
    • Ages 12 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Michigan ( Site 0126)
    Registry record
    NCT04924075 · updated
  2. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US006
    Registry record
    NCT07522073 · updated
  3. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    University of Michigan
    Registry record
    NCT07644559 · updated
  4. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Trinity Health Saint Joseph Mercy Hospital Ann Arbor · University of Michigan Rogel Cancer Center
    Registry record
    NCT04858334 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Ann Arbor, MI on ClinicalTrials.gov.

Ask about studies near Ann Arbor

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Michigan

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call